Currently, the development of effective diagnostic reagents as well as treatments against Hepatitis C virus (HCV) remains a high priority. In this study, we have described the development of an alive cell surface -Systematic Evolution of Ligands by Exponential Enrichment (CS-SELEX) technique and screened the functional ssDNA aptamers that specifically bound to HCV envelope surface glycoprotein E2. Through 13 rounds of selection, the CS-SELEX generated high-affinity ssDNA aptamers, and the selected ssDNA aptamer ZE2 demonstrated the highest specificity and affinity to E2-positive cells. HCV particles could be specifically captured and diagnosed using the aptamer ZE2. A good correlation was observed in HCV patients between HCV E2 antigen-aptamer assay and assays for HCV RNA quantities or HCV antibody detection. Moreover, the selected aptamers, especially ZE2, could competitively inhibit E2 protein binding to CD81, an important HCV receptor, and significantly block HCV cell culture (HCVcc) infection of human hepatocytes (Huh7.5.1) in vitro. Our data demonstrate that the newly selected ssDNA aptamers, especially aptamer ZE2, hold great promise for developing new molecular probes, as an early diagnostic reagent for HCV surface antigen, or a therapeutic drug specifically for HCV.
Citation: Chen F, Hu Y, Li D, Chen H, Zhang X-L (2009) CS-SELEX Generates High-Affinity ssDNA Aptamers as Molecular Probes for Hepatitis C Virus Envelope Glycoprotein E2. PLoS ONE 4(12): e8142. https://doi.org/10.1371/journal.pone.0008142
Editor: Stefan Bereswill, Charité-Universitätsmedizin Berlin, Germany
Received: October 18, 2009; Accepted: October 29, 2009; Published: December 3, 2009
Copyright: © 2009 Chen et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by grants from the National Natural Science Foundation of China (20532020, 30670098, and 30870122), the 973 Program of China (2006CB504300, 2009CB522507), the Hubei Province Natural Science Foundation (2006ABD007), and National Grand Program on Key Infectious Disease (2008ZX10003-005). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing interests: Authors declare that there are patent applications for this work and aptamers sequences.
Hepatitis C virus (HCV) is estimated to have infected 3% of the world's population (approximately 170 million people). Approximately 80% of the infected patients develop liver cirrhosis and, in some cases, hepatocarcinoma , . Recent reports have shown more HCV recurrence and decreased survival for HCV following orthotopic liver transplantation or insulin resistance in patients with chronic hepatitis C , . In addition, there is a high prevalence of HCV, HIV, and hepatitis B virus (HBV) coinfection, which requires that the access to diagnosis and therapies for these infections is improved. Presently, the only available therapy is alpha interferon (IFN-α) alone or in combination with ribavirin –. Such treatments are expensive, show low response rates, and carry the risk of significant side effects –. Effective therapies to counteract this important public health problem are still lacking.
Early diagnosis of HCV infection in HCV- or HIV-infected patients has significant implications for patient management. However, the currently recommended serological screening strategy for identifying anti-HCV antibodies is unable to detect plasma donations that are anti-HCV-negative and HCV RNA-positive during the pre-seroconversion window period (PWP). Another method for detecting HCV RNA is reverse transcript polymerase chain reaction (RT-PCR), which is not feasible due to its high cost; it is not used routinely in the diagnostic laboratories, especially in developing countries , . The latest breakthrough in diagnosing early HCV infection is by detecting the HCV core antigen that is present during the early stage or before seroconversion . However, relying solely on a single HCV core antigen assay may not be useful for a definite diagnosis of early HCV infection. None of the current methods are available to measure the HCV surface antigens in serum. More sensitive and less expensive assays for the early diagnosis of HCV are needed.
HCV is a member of the Flaviviridae family and is an enveloped virus with a single-stranded RNA genome approximately 9.5 kb in length that contains a single open reading frame –. The open reading frame encodes a polyprotein of approximately 3,010 amino acids that is processed into at least 10 mature proteins (C, E1, E2, p7, NS2, NS3, NS4A, NS4B, NS5A, and NS5B) by both host signal peptidases and viral proteases. HCV contains two heavily glycosylated envelope glycoproteins, E1 and E2. E2 is thought to initiate viral attachment , whereas E1 may be involved in virus-cell membrane fusion. The envelope E2 glycoprotein plays a critical role in the initiating infection through recognizing and binding to human cellular receptors –. It has been proposed that the E2 glycoprotein binds to CD81, a tetraspanin molecule that is expressed on hepatocytes and B lymphocytes. HCV infection is dependent on at least three co-receptors: CD81, scavenger receptor BI (SR-BI), and claudin-1 –. Among them, CD81 has been identified as a critical co-receptor for HCV particle entry –.
High affinity aptamers for specific target molecules can be isolated from a library of randomized sequences in vitro using the SELEX (systematic evolution of ligands by exponential enrichment) process . SELEX involves sequential rounds of selection and amplification from a vast pool of nucleic acids (1014 molecules) for ligands (aptamers) that bind with high affinity to target molecules. Aptamers are short, single-stranded oligonucleotides that can fold into specific three-dimensional structures in order to recognize target molecules, such as small chemicals, proteins, or even cells; as such, they have several potential advantages over antibodies and antibiotics. Being smaller than antibodies, aptamers are better candidates for cell penetration and blood clearance. Aptamers have been used for pure recognition, inhibition, diagnostic, and therapeutic applications .
Small aptamers that inhibit the virus at the stage of viral entry (e.g., by blocking the interactions between the viral envelope glycoprotein and the cellular receptor or co-receptor) have not been described so far. Several aptamers have been selected against HCV –. However, none of these have been selected against surface envelope glycoproteins. Currently, few SELEX strategies exist to generate inhibitors against glycosylated viral envelope proteins.
In the present study, we developed a new SELEX procedure termed alive cell surface-SELEX (CS-SELEX), which targets the E2 envelope glycoprotein expressed on the mammalian cell line CT26. In this model system, we carried out CS-SELEX by establishing a stable cell line that ectopically expressed the HCV E2 glycoprotein on the cell surface and examined the binding affinities and functions of selected ssDNA aptamers.
High-affinity Aptamers for HCV-E2 Glycoprotein Were Isolated by CS-SELEX
To isolate aptamers that specifically bind to the HCV E2 envelope glycoprotein, we utilized E2-expressing CT26 cells as a selection target; CT26 cells were used for counter selection. Our approach relies on CS-SELEX to evolve aptamers for whole live cells that express a variety of surface markers representing molecular differences among E2-CT26 cells and CT26 cells. The random ssDNA library (ca.1014 molecules) was used to screen ligands that bind to E2-CT26 cells (Fig. 1A). Aptamers that bind to E2-CT26 cells with high affinity and specificity were successfully obtained.
(A) The E2 stably expressing cell line E2-CT26 was established, and E2-CT26 E2 cell surface expression was identified by a PE-conjugated anti-E2 antibody using flow cytometry. (B) Comparison of binding percentages of different pools of FITC-labeled aptamers with E2-CT26 cells using flow cytometry. Data shown were calculated as mean±SEM, and data are from three independent experiments. (C) Representative results from different pools of FITC-labeled aptamers binding with E2-CT26 cells by flow cytometry.
After 14 rounds of selection, different pools of aptamers were obtained using CS-SELEX, and the binding affinities between aptamers and E2-CT26 cells were measured by flow cytometry as described in the Methods. The sequence of binding affinities between FITC-labeled aptamers was as follows: 13th Pool>12th Pool>10th Pool>14th Pool>1st Pool, as shown in Figs. 1B and 1C.
The 13th Pool clones were cloned into pUC19, and individual clones of single aptamers were selected and sequenced. The consensus regions within the individual aptamers are shown in Table 1. The single aptamer ZE2 has the highest binding affinity among all aptamers with a Kd of 1.05±1 nM. The sequence of binding affinities was as follows: ZE2 (Kd 1.05±1 nM)>13th P (Kd 1.67±0.9 nM)>ZE3 (Kd 3.22±0.7 nM)>12th P (Kd 6.34±0.9 nM)>ZE5 (Kd 4.29±0.6 nM)>ZE4 (Kd 8.85±1 nM)>10th P (Kd 16.6±6 nM) (Table 2).
The SsDNA Aptamer ZE2 with the Highest Binding Affinity Specifically Targets HCV E2
The single aptamer ZE2 was chosen for further characterization, as it had the highest E2 binding affinity. Firstly, the interaction between the ssDNA aptamer ZE2 and the E2 protein was demonstrated by capillary zone electrophoresis. The GST-E2 and GST recombinant proteins were purified and confirmed using SDS-PAGE and western blot analysis (Fig. 2A). The capillary electrophoresis method is based on simple UV detection at 260 nm with a linear polymer buffer and a coated capillary; it requires no labeling or derivatization of the DNA. We observed that the DNA aptamer ZE2 was facilely adsorbed to the GST-E2 protein but not to the GST protein (Fig. 2C), and the binding was completed within 10 min. A specific E2 protein-DNA aptamer ZE2 complex was observable as a retarded peak, which increased with increasing protein concentration with a corresponding reduction in the free DNA peak (Fig. 2B).
(A) SDS-PAGE (Left) and western blot analysis (Right) of the purified GST-E2 and GST recombinant proteins. (B) Capillary electrophoresis analysis of single aptamer ZE2 binding to different doses of GST-E2 protein. Representative results of CEMSA showed that the binding peak of ZE2 with GST-E2 migrated from left to right, but the binding peak of ZE2 with GST had no change.
Fluorescence Microscope Imaging of E2-expressing Cells with FITC-ZE2 Aptamer
The secondary structure of the ssDNA aptamer ZE2 was predicted with the DNAMAN software (Lynnon Biosoft), and it showed that the terminal loop of a stem-loop structure might be the site of binding to the target E2 protein (Fig. 3A). To test this possibility, a ssDNA aptamer ZE2-mut was synthesized, in which two bases in the terminal loop of a stem-loop structure of ZE2 were mutated (Fig. 3A). We further observed that E2-expressing cells, E2-HepG2, specifically bound FITC-ZE2 aptamers under the fluorescence microscope (Figs. 3B and 3C). The fluorescence intensities of the binding affinities between FITC-ZE2 and E2-expressing cells were aptamer dose-dependent (Fig. 3C), and a much smaller fluorescence intensity was observed when using the FITC-ZE2-mut (Fig. 3C). Similar results were observed for fluorescence microscope imaging of E2-CT26 cells bound with the FITC-ZE2 aptamer (data not shown). No binding between FITC-ZE2 and HepG2 or CT26 cells was detected (Figs. 3B and 3C).
(A) Prediction of ZE2 secondary structure. Arrows represent exchanged bases in ZE2-mut compared to that of the ZE2 aptamer. (B) Fluorescence microscope imaging of E2-expressing cells with FITC-ZE2. FITC-ZE2 bound to E2-HepG2 cells but not to HepG2 cells by confocal immunofluorescence microscopy. (C) Comparison of different doses of FITC-ZE2 or FITC-ZE2-mut binding to the E2-HepG2 or HepG2 cells by confocal immunofluorescence microscopy.
The above data suggest that the ssDNA aptamer ZE2 specifically targets HCV envelope glycoprotein E2-expressing cells, and FITC-ZE2 can be used as a probe to detect E2-expressing cells using a fluorescence microscope.
The ssDNA Aptamer ZE2 Specifically Targets HCV Particles
To determine whether this selected aptamer ZE2 could bind to HCV particles, virus capture assays were performed by sandwich ELISA. Virus samples from HCVcc were incubated in the anti-E2 polyclonal antibody-precoated ELISA plates. Biotin-aptamers were then added and incubated, followed by extensive washing to remove unbound aptamers. The bound viral particles were revealed by the biotin-labeled aptamers as described in the Materials and Methods. We found that ZE2 aptamer binding to the HCV particles was aptamer dose-dependent, but the ZE3 aptamer or the ZE2-mut with two mutated bases had a much lower binding affinity (Fig. 4A). These results are consistent with their binding affinities with E2 glycoprotein. No binding was observed between the ZE2 aptamer and control culture media (Fig. 4A).
(A) HCVcc could be captured by the aptamer ZE2 in an aptamer dose-dependent manner by sandwich ELISA. Plates were coated with anti-E2 polyclonal antibody and blocked with 1% BSA. After extensive washing, the bound viral particles were added and then revealed using biotin-labeled aptamer ZE2, ZE3 or ZE2-mut as described in Materials and Methods. Data shown were calculated as mean±SEM, and data are from three independent experiments. (B) Comparison of HCV detection methods: HCV E2 antigen-aptamer method and HCV RNA quantification by real time fluorescence quantitative RT-PCR. The aptamer method was performed as above (A), except HCV patients and healthy donor serum samples were added into each 96-well ELISA plate instead of HCVcc. (C) Determination of E2 protein expressions of different genotypes of E1E2 gene stable-expressing HepG2 cells with anti-E2 antibody by western blot analysis. HepG2 was uesd as a control. (D) Different genotypes of E2 detected by aptamer ZE2. Data shown were calculated as mean±SEM and data are from three independent experiments.
In addition, sera samples from 154 Chinese HCV patients (both HCV antibody- and HCV RNA-positive) and 155 healthy donors (both HCV antibody- and HCV RNA- negative) were collected and measured using the biotin-ZE2 probe with sandwich ELISA. As shown in Table 3 and Fig. 4B, a good correlation was observed between HCV E2 antigen-aptamer assay and assays for HCV RNA quantities or HCV antibody detection. Biotin-labeled ZE2 could bind to HCV particles in HCV patient samples with much higher affinities than to healthy donor samples (* p<0.05, Table 3, Fig. 4B), and the absorbance values of the HCV serum samples were not only proportional to serial dilutions of sera, but also to HCV RNA copies measured by RT-PCR (Fig. 4B).
These data suggest that the ssDNA aptamer ZE2 specifically targets HCV particles and could be used to diagnose early HCV infection by detecting HCV surface antigen in sera that is present during the early stage or before seroconversion.
Genotypes 1a, 1b, and 2a of E2 Can be Significantly Captured by Aptamer ZE2
HCV has six major genotypes and numerous subtypes based on its positive-strand RNA genome, and a seventh major genotype was recently discovered . E1E2 gene (from genotypes 1 to 6) stable-expressing HepG2 cells were established by G418 selection, and E2 expressions from these cells were determined by western blot analysis (Fig. 4C). Different genotypes of E1E2 gene stable-expressing HepG2 cells were used to coat ELISA plates. We utilized ELISA to determine which genotypes of E1E2 could be bound by ZE2. The results showed that aptamer ZE2 was specifically targeted to the E2 proteins of genotypes 1a, 1b, and 2a, and the binding affinities of aptamer ZE2 with genotypes 1a, 1b, and 2a of E2 were three to five-fold higher than those of genotypes 3, 4, 5, and 6 (Fig. 4D).
Selected Aptamers Block E2 Protein Binding to Target Huh7.5.1 Cells
As the aptamer ZE2 specifically binds to HCV E2, we next further determined whether aptamer ZE2 also has the ability to block HCV E2 binding to its target cells. Human hepatocyte Huh7.5.1 cells are supposed to express the HCV E2-binding receptor CD81, and human CD81 has been described as a main receptor for HCV (16–20). We used a PE-labeled anti-CD81 antibody to detect whether Huh7.5.1 cells expressed CD81. A flow cytometric analysis showed that PE-labeled anti-CD81 antibody bound to Huh7.5.1 cells with a much higher binding affinity than that of the PE-labeled control antibody (Ab) (Fig. 5A). When the E2 or GST proteins were added, Huh7.5.1 cells significantly bound to the E2 protein (Fig. 5B), and their binding affinities were much higher than they were for the control GST protein (Fig. 5B, * p<0.05). The E2 protein specifically bound to Huh7.5.1 cells but not to CT26 cells (Fig. 5B). All of the above data suggest that Huh7.5.1 cellular surfaces have HCV E2-binding CD81 receptor molecules.
(A) CD81 molecules are expressed on the cellular surface of hepatocytes Huh7.5.1; flow cytometric analysis with PE-labeled anti-CD81 antibody. PE-conjugated rat IgG1 was used as an isotype-matched control antibody (Ab). (B) HCV E2 had a much higher binding affinity for Huh7.5.1 than CT26 cells by flow cytometric analysis. E2-GST or GST proteins were preincubated with 1×106 Huh7.5.1 or CT26 cells, respectively. Anti-GST antibody and FITC-anti-IgG were added and analyzed by flow cytometric analysis. (C) Different pools of aptamers or single DNA aptamer ZE2 can block HCV E2 protein binding to Huh7.5.1 cells. (D) GST and ZE2 do not bind to huh7.5.1 cells by flow cytometric analysis. (E) CD81 competitively blocked FITC-aptamer binding to E2-CT26 cells by flow cytometric analysis. (F) Both ZE2 and CD81 competitively blocked E2 binding to Huh7.5.1 cells, as determined by flow cytometry with FITC-conjugated anti-E2 antibody. All data are mean±SEM from six separate experiments.
The flow cytometric experiments revealed that the selected aptamers significantly blocked HCV E2 protein binding to Huh7.5.1 cells (Fig. 5C). The sequence of inhibition effects was as follows: ZE2>13th P>6Th P (Fig. 5B). The inhibitory effects of the aptamers were consistent with their binding affinity results shown in Table 1. However, GST and ZE2 had no significant binding affinities for Huh7.5.1 cells (Fig. 5D). The recombinant CD81 protein could competitively inhibit the aptamers from binding to the E2-expressing cells (E2-CT26), especially ZE2 and the 13th pool aptamers (Fig. 5E), while no or weak inhibitory effects were observed for the 4th and 12th pool aptamers (Fig. 5E), which due to their less binding affinities to E2 comparing the 13th pool aptamers and ZE2 aptamer (Table 2). Moreover, ZE2 or CD81 blocked approximately 80% of HCV E2 protein binding to CD81-expressing Huh7.5.1 cells, respectively (Fig. 5F). The addition of both ZE2 and CD81 blocked approximately 90% of HCV E2 protein binding to Huh7.5.1 cells (Fig. 5F). All of these data indicate that ZE2 and CD81 may share similar binding sites on HCV E2 and that aptamer ZE2 can block HCV E2 binding to target Huh7.5.1 cells.
Aptamer ZE2 Dramatically Inhibits HCV Infection of Huh7.5.1 Cells
Finally, we examined the inhibitory effects of aptamer ZE2 on HCV infection of human hepatocyte Huh7.5.1 cells. Immunofluorescence microscopy demonstrated that the mean fluorescence intensities (MFIs) of intracellular HCV were significantly decreased upon the addition of the ZE2 aptamer or IFN-α (Fig. 6A). While the ZE2-mut and ZE3 had lower inhibitory effects on viral infection compared to ZE2 (Fig. 6A). These results are consistent with their binding affinities with E2 glycoprotein. The intracellular HCV E2 protein and viral RNA levels were further determined by western blotting (Fig. 6B) and real-time RT-PCR analysis, respectively (Fig. 6C). Both the western blot and real-time RT-PCR showed that there was a dose-dependent inhibitory effect of the aptamer ZE2 on viral infection, and the inhibitory effect of 100 nM ZE2 aptamer was virtually equivalent to that of 500 IU IFN-α (Figs. 6B and 6C). These data illustrate that aptamer ZE2 may indeed block and inhibit viral infection of human hepatocytes.
(A) Immunofluorescent detection of intracellular HCV mean fluorescence density (MFI) of HCVcc infected Huh-7.5.1 cells with anti-E2 antibody. The data shown were calculated as mean±SEM and data are from three independent experiments. (B) Western blot analysis of intracellular E2 protein expressions of HCVcc infected Huh7.5.1 in the presence of ZE2 or IFN-α with specific anti-E2 antibody; β-actin, a housekeeping gene with constant expression, was used as internal control. β-actin protein was detected with specific anti- β-actin antibody. (C) Quantitation of intracellular HCV RNA was detected using real-time quantitative RT-PCR and normalized to the levels of GAPDH mRNA. GAPDH, a housekeeping gene with constant mRNA expression, was used as internal control. The data shown were calculated as mean±SEM and data are from three independent experiments.
This study shows that the ssDNA aptamers that bind specifically to HCV-E2 have been successfully generated by CS-SELEX for the first time. In contrast to most described SELEX methods, our approach relies on CS-SELEX to evolve aptamers for whole live cells that express a variety of surface markers representing molecular differences among different cells. The aptamers selected from CS-SELEX for whole live cells have much higher specificity than those aptamers from SELEX for a single target molecule. Most importantly, the aptamers we selected here bound to the natural form of the E2 envelope glycoprotein expressed on the mammalian CT26 cells, with glycosylation modifications that can affect protein folding, structure, and function. In addition, our approach involves DNA aptamers, which present several advantages over RNA aptamers, such as their increased stability, long shelf-life, and ease of chemical synthesis in large quantities at a relatively low cost.
Our finding firstly identified that the ZE2 ssDNA aptamer was able to identify the presence of HCV E2 surface antigen or free E2 antigen in HCV patient serum samples by a simple ELISA method. This method was highly consistent with the detectable results of HCV antibody and HCV RNA of HCV patient serum samples (Table 3, Fig. 4B). These data suggest that the ssDNA aptamer ZE2 could be used to diagnose early HCV infection by detecting the HCV surface antigen that is present in sera during the early stage of infection or before seroconversion. Furthermore, the ssDNA aptamer ZE2 could specifically target HCV envelope glycoprotein E2-expressing cells (Figs. 3B and 3C), and FITC-ZE2 seemed to be promising as a probe to detect HCV-infected cells. Such technology could be used both in vitro and in vivo for animal experiments in concert with fluorescence microscopy and optical in vivo imaging technology, respectively.
The limitations of the detection of anti-HCV antibodies or HCV RNA in serum currently used for the diagnosis of HCV infection have enhanced efforts to find a rapid, simple, sensitive, and specific alternative diagnostic approach to detect viral antigens. Similar to the detection of Hepatitis B Virus (HBV) surface antigen for the diagnosis of HBV infection, the ZE2 DNA aptamer may be helpful for the diagnosis of early HCV infection through a simple ELISA method to detect HCV E2 envelope surface antigen. Although HCV E2 contains 1∼2 amino acid sequence hypervariable regions (HVR) but most of the E2 residues, the chemicophysical properties and conformation of HVR are highly conserved . CD81 is a conserved receptor for HCV E2 binding. The DNA aptamer ZE2 and CD81 share similar binding sites on HCV E2 (Fig. 5). Therefore, the DNA aptamer ZE2 holds great potential for the detection of HCV surface antigen in both clinical applications and basic research.
Based on genetic differences between HCV isolates, HCV has been classified into six genotypes (through 1–6) with several subtypes within each genotype (represented by letters) . The preponderance and distribution of HCV genotypes varies globally. For example, in North America, genotype 1a predominates followed by 1b, 2a, 2b, and 3a. In Europe, genotype 1b is predominant followed by 2a, 2b, 2c, and 3a. Genotypes 4 and 5 are found almost exclusively in Africa . The most common genotypes of HCV in China and Korea are subtypes 1b and 2a, followed by 1a or 6 , . Genotype is clinically important in determining the potential patient response to interferon-based therapy and the required duration of such therapy. Our results showed that genotypes 1a, 1b, and 2a of E2 could be significantly captured by aptamer ZE2, and the binding affinities of aptamer ZE2 with genotypes 1a, 1b, and 2a of E2 were two-fold higher than those of genotypes 3, 4, 5, and 6 (Fig. 4D). Our experiments suggest that ZE2 can detect HCV particles in the sera of Chinese patients (Table 3). ZE2 may also hold great potential for use in the early diagnosis of HCV in Korea, the Americas, Europe, and Japan, and could also be helpful in determining the potential response to interferon-based therapeutic monitoring and prognostics.
Finally, we found that the DNA aptamer ZE2 could partially block HCV E2 binding to the CD81 receptor (Fig. 5F) and subsequent viral entry and infection of human hepatocytes (Fig. 6). These data suggest that DNA aptamer ZE2 may also hold potential for use as a drug against HCV infection, which is strengthened by its low immunogenicity and ease of chemical synthesis in large quantities at a relatively low cost. An anti-VEGF therapeutic aptamer was the first approved by the FDA for macular degeneration . A second aptamer targeting the coagulation factor IXa is currently being tested as an anticoagulant in phase I/II clinical trials . The newly selected aptamers, especially ZE2, are worthy of further clinical and basic research.
In summary, our data demonstrate that the selected aptamers, especially ZE2, hold great promise for developing new molecular probes as early diagnostic reagents or therapeutic drugs targeting HCV. Aptamers can also serve as tools for analyzing HCV-host cell interactions both in vitro and in vivo. The experimental strategy described in this study should be applicable for developing agonistic aptamers targeting a broad range of cell surface-expressed envelope glycoproteins of other viruses. The approach described here thus provides a new set of tools to screen early diagnostic reagents or therapeutic drugs against human viral diseases.
Materials and Methods
Cells and plasmids
Murine colon carcinoma cell line CT26 cells  were cultured in RPMI-1640 medium with 10% (v/v) fetal bovine serum (Hyclone). Rabbit anti-E2 polyclonal antibody was prepared as in our previous publication . Human hepatocellular liver carcinoma cells Huh-7.5.1  and HepG2  were used in this study. HCV cell culture (HCVcc)-JFH-1 (2a) and Huh-7.5.1 cells were derived from Huh-7.5, which was kindly provided by Wen-Zhe Ho from the University of Pennsylvania School of Medicine . Cloned E1E2 genes of HCV genotypes 1 through 6 in a pcDNA3 expression vector were kindly provided by Dr. Jonathan K. Ball from the University of Nottingham . E1E2 gene stable-expressing HepG2 cells, E2 (genotype 1a) surface-expressing HepG2 (E2-HepG2), and CT26 (E2-CT26) stable cell lines were established by G418 selection . E. coli BL21(DE3)/plysS and E. coli DH5α were used as described previously . The bacteria were harvested by centrifugation at 13,000×g and suspended in sterile PBS at the appropriate concentration. Bacterial CFUs (colony forming units) were quantified from the absorbance at 600 nm. The CD81 recombinant protein was kindly provided by Dr. Zhongtian Qi of the Second Military Medical University in China .
HCV serum samples or healthy serum samples were collected from 2006 to 2008 in Zhongnan Hospital of Wuhan University, Wuhan, China. The ethical approval for this study was obtained from the Zhongnan Hospital Research Ethics Committee. Written informed consents were obtained from all individuals.
Getting the aptamers by Cell Surface- SELEX (CS-SELEX)
The CS - SELEX procedures were primarily based on our previous work , . The library construction was designed, and random oligonucleotide templates were synthesized as a single-stranded 88-mer with the following sequence: 5′-GCGGAATTCTAATACGACTCACTATAGGGAACAGTCCGAGCC-N30-GGGTCAATGCGTCATA-3′, where the central N30 represents random oligonucleotides based on equal incorporation of A, G, C, and T at each position , . The complementary strand was synthesized using the DNA polymerase I Klenow fragment with primer 1: 5′-GCGGGATCCTATGACGCATTGACCC-3′, where the underlined portion represents a BamHI site. The initial dsDNA random library was generated by PCR amplification using primer 1 and primer 2: 5′-GCGGAATTCTAATACGACTCACTATAGGGAACAGT-3′, which contains an EcoRI site (underlined) , . PCR reactions were performed as follows: a 100 µl of PCR mixture contained 10 µl of 10x PCR buffer, 0.2 mM dNTPs, 0.5 µM each primer, 10 nM template, and 2.5 U Taq DNA polymerase. The mixture was thermally cycled 30 times through 95°C for 1 min, 37°C for 30 s, and 58°C for 40 s, followed by a 5 min extension at 58°C. The ssDNA random library was then obtained by heating the dsDNA library at 85°C for 15 min and snap-cooling on ice for 3 min.
To initiate in vitro selection, random ssDNAs were incubated in binding buffer (25 mM Tris–HCl, 50 mM KCl, 200 mM NaCl, 0.2 mM EDTA, 5% (v/v) glycerol, and 0.5 mM DTT) for 30 min at 37°C, together with 106 E2-CT26 cells. Following a wash with at least 40 column volumes of binding buffer, bound ssDNA was centrifuged at 12,000 rpm for 5 min, and the supernatant was discarded. The precipitant was diluted by adding 50 µL sterile ddH2O, boiled for 5 min, snap-cooled on ice for 3 min, extracted by phenol/chloroform (25∶24), and the supernatant was used as the template for PCR to obtain the ssDNA pool for the next round of selection. To remove nonspecifically bound DNA, we applied the counter-selection step using CT26 cells followed by the selection of E2-CT26 cells in each cycle. Each pool of aptamers was obtained by a different round of selection. The PCR products of each round were digested with EcoRI and BamHI and then subcloned into pUC19. The bank was transformed into E. coli DH5α. Plasmid DNA was isolated from individual clones, purified, and analyzed by sequencing. Individual aptamers were obtained.
Flow cytometry analysis
FITC-labeled aptamer pools or individual aptamers were obtained by PCR using FITC-labeled primers. Individual aptamers could also be synthesized according to their sequence. To demonstrate the binding specificity and characterize the binding parametersof the aptamers to E2 glycoprotein, FITC-labeled aptamers (250 nM) were incubated with 106 E2-HepG2 (or E2-CT26), or HepG2 (or CT26) cells at 37°C for 15 min. They were then centrifuged at 2,000 rpm for 5 min, and the supernatant was discarded. The stained cells were then analyzed in a Beckman Coulter EPICS ALTRA II flow cytometer. The binding affinities of the individual aptamers to E2 glycoprotein-expressing cells were obtained by monitoring the mean fluorescence intensity of target E2-expressing cells bound to the FITC-labeled aptamers using a flow cytometer as described . The concrete steps were the same as the flow cytometry analysis. The equation Y = BmaxX/(Kd+X) (Origin Pro 7.5) was used to calculate the target antigen-binding equilibrium dissociation constant Kd, where Bmax is the maximum percentage of fluorescence, Y is the mean percentage fluorescence, and X is the molecule mol concentration.
To detect whether the selected aptamer, ZE2, and CD81 share similar binding sites on the HCV E2 protein, 20 µg of recombinant CD81 proteins were incubated with 1×106 E2-CT26 cells and then incubated with FITC-labeled aptamers (250 nM) at 37°C for 1 hr. The binding affinities between E2-CT26 cells and FITC-labeled aptamers were analyzed using flow cytometry. PE-, or FITC-conjugated rat IgG1 were used as an isotype-matched control.
Capillary electrophoretic mobility shift assay (CEMSA)
GST-E2, or GST recombinant proteins were purified according to our previous publication . In the analysis of the interaction between aptamers and E2 or GST proteins, CEMSA was performed on a Beckman P/ACE 5000 system (Fullerton, CA, USA). A series of mixtures with a fixed concentration of aptamers (250 nM) and increasing concentrations of E2, GST, or E2-GST recombinant proteins was prepared. The concentrations of the proteins in the mixtures were 0, 0.151, 0.302, 0.453, 0.604, and 0.755 µM, respectively. The mixtures were allowed to remain at equilibrium for 30 min at 4°C and were then injected using the pressure injection mode at 0.5 psi for 10 s.
Fluorescence microscope imaging of E2-expressing cells bound with aptamers
The FITC-labeled aptamers (250 nM each) were incubated with 105 E2-HepG2, or E2-CT26, or CT26 cells per well in 6-well plates with a cover slide in each well at 4°C overnight in the dark. The unbound aptamers in the supernatant were then discarded. The cell–ssDNA complex sediment was washed three times with PBS. Cells were then fixed with 4% paraformaldehyde and permeabilized with buffers containing 0.5% Triton X-100, 0.1% SDS, and 50 mmol/L Tris (pH 8.0). The fixed cells were stained with 100 µg/ml of the DNA-binding dye Propidium Iodide (PI) (Sigma) at room temperature for 5 min. The cells were washed three times with PBS. Imaging of the cells on the cover slide was performed with a confocal fluorescence microscope (Leica DM RXA) under 488 nm exciting light (green for FITC and red for PI) and visible light.
Enzyme-Linked Immunosorbent Assay (ELISA)
A sandwich ELISA was performed for the virus capture assays using aptamers. The anti-E2 polyclonal antibody was coated into each well of a 96-well plate at 4°C overnight. After washing, the plates were blocked with 2% bovine serum albumin (BSA). After washing with phosphate-buffered saline (PBS)-0.1%(w/v) Tween-20 (PBST), 100 µL of the serum samples or HCVcc (4×105 copies virus in 180 µl per well) was added to each well and incubated at 37°C for 30 min. HCV serum samples or healthy serum samples were collected from 2006 to 2008 (viral titer determined by real-time quantitative RT-PCR; provided by Zhongnan Hospital, Wuhan University, China). The plates were then washed, and the biotin-labeled aptamer (100 µL; 250 nM) was aliquoted into each well. After incubation at 37°C for 30 min, a 1∶1000 dilution of HRP-streptavidin was added and incubated at 37°C for 30 min. Finally, the samples were developed with a substrate solution containing o-phenylenediamine. The absorbance of each sample was measured at 450 nm.
To analyze the binding affinities between the aptamers and the E1E2 glycoproteins of different genotypes (genotypes 1 through 6), 96-well ELISA plates were pretreated by coating them with 100 µg/mL poly-L-lysine. After incubating at room temperature (RT) for 1 hr, the solution was removed, and the plates were rinsed with water and dried. Different genotypes of E1E2 gene stable-expressing HepG2 cells were established by G418 selection and coated in the 96-well plates. After washing, 100 µL of the biotin-labeled aptamers (250 nM) was added to each well. The same steps as described above were then followed.
Measurement of anti-HCV antibody in the serum
Each fresh plasma sample was tested with an HCV antibody ELISA assay kit (KHB, Shanghai kehua Co. P. R. China), and HCV-positive samples (a sample-to-cut-off ratio (S/CO) higher than 1) were kept frozen until use.
Measurement of inhibitory effects of aptamers on HCVcc infection by fluorescence microscopy analysis
JFH-1 HCVcc (JFH-1; 10 µL; 1×105 copies of virus) was pre-incubated with the different doses of ssDNA aptamers at 37°C for 1 hr and then added to the 96-well plates with Huh-7.5.1 cells (4.5×105/well) in DMEM with 10% FBS. After a 12 hr incubation, the virus-containing supernatant was removed and replaced by fresh media. Cells were incubated at 37°C for 72 hrs. Cells were washed with PBS and fixed for 20 min at room temperature in 4% paraformaldehyde. The cells were then washed with PBS containing 0.2% BSA. Fluorescence-labeled anti-E2 antibody was added to the Huh7.5.1 cells, incubated for 4 h, and washed with PBS three times. HCVcc-infected Huh7.5.1 cells were detected and measured by fluorescence microscopy.
RNA quantification by real time fluorescence quantitative RT-PCR
Huh7.5.1 cells were cultured in a 6-well plate at a concentration of 5×105 cells/well. Different concentrations of aptamers, aptamer mutants, or 1×104 IU IFN-α were added to the cells along with 6×105 viral copies of JFH-1 HCVcc. The mixtures were incubated at 37°C overnight. Cells were washed with DEPC-treated PBS to remove HCVcc in the supernatant, and total RNA was extracted from HCVcc-infected or non-infected Huh7.5.1 cells using Trizol reagent (Invitrogen Life Technologies); the RNA was then reverse transcribed using the First Strand cDNA synthesis kit (Fergment). The HCV primers were designed based on the HCV sequence (GenBank Accession # M67463) selected within the 5′-noncoding region (NCR) of the HCV genome according to our previous method . RNA was quantitated by the real-time reverse transcription polymerase chain reaction (RT-PCR) using the QuantiTectTM SYBR Green PCR Handbook Kit (QIAGEN) with the primers P1: 5′-CGGGAGAGCCATAGTGGTCTGCG-3′ (130∼152 nt) and P2: 5′-CTCGCAAGCACCCTATCAGGCAGTA-3′ (287∼311 nt) (i.e., specific for HCV), or the primers GAPDH-F: 5′–ACCACAGTCCATGCCATCAC–3′ and GAPDH-R: 5′–TCCACCACCCTGTTGCTGTA–3′ (i.e., specific for housekeeping gene GAPDH). The results were analyzed using Rotogene 6.0 software.
Western blot analysis
Huh7.5.1 cells were cultured in a 6-well plate at a concentration of 5×105 cells/well. Different concentrations of aptamers, aptamer mutants, or 500 IU IFN-α were added to the cells along with 6×105 viral copies of JFH-1 HCVcc. The mixture was incubated at 37°C overnight, and cells were washed with PBS and lysed with 200 µl SDS-loading buffer. Samples were then boiled for 5 min and loaded onto a 12% SDS-polyacrylamide gel. After electrophoresis, proteins were transferred to a PVDF membrane, and E2 protein was detected with a specific anti-E2 polyclonal antibody; β-actin protein was detected with a specific anti-β-actin antibody.
We deeply appreciate Drs. Wen-Zhe Ho, Dr. Jonathan K. Ball and Dr. Zhongtian Qi for their kindly providing experimental materials for this work. We thank all the members in our laboratory for their help.
Conceived and designed the experiments: FC YH DL HC XLZ. Performed the experiments: FC YH DL HC. Analyzed the data: FC YH DL HC XLZ. Contributed reagents/materials/analysis tools: XLZ. Wrote the paper: XLZ.
- 1. Memon MI, Memon MA (2002) Hepatitis C: an epidemiological review. J Viral Hepatitis 9: 84–100.
- 2. Gottwein JM, Bukh J (2008) Cutting the Gordian knot-development and biological relevance of hepatitis C virus cell culture systems. Adv Virus Re 71: 51–133.
- 3. Hsu CS, Liu CJ, Liu CH, Wang CC, Chen CL, et al. (2008) High hepatitis C viral load is associated with insulin resistance in patients with chronic hepatitis C. Liver Int 28: 271–277.
- 4. Smallwood GA, Devine R, Fasola C, Stieber AC, Heffron TG (2008) Does interferon use prior to liver transplant influence hepatitis C outcomes following transplantation? Transplantation, 86: 1795–1798.
- 5. Liu CH, Liu CJ, Lin CL, Liang CC, Hsu SJ, et al. (2008) Pegylated interferon-alpha-2a plus ribavirin for treatment-naive Asian patients with hepatitis C virus genotype 1 infection: a multicenter, randomized controlled trial. Clin Infect Dis 47: 1260–1269.
- 6. Bellecave P, Moradpour D (2008) A fresh look at interferon-alpha signaling and treatment outcomes in chronic hepatitis C. Hepatology 48: 1330–1333.
- 7. Boyer N, Marcellin P (2000) Pathogenesis, diagnosis and management of hepatitis C. J Hepatol 32: 98–112.
- 8. Sarasin-Filipowicz M, Oakeley EJ, Duong FH, Christen V, Terracciano L, et al. (2008) Interferon signaling and treatment outcome in chronic hepatitis C. Proc Natl Acad Sci USA 105: 7034–7039.
- 9. Menegazzi P, Reho E, Ulivi M, Varnier OE, Lillo FB, et al. (2008) Rapid and accurate quantification of different HCV genotypes by LightCycler Real Time PCR and direct sequencing of HCV amplicons. New Microbiol 31: 181–187.
- 10. Cock De L, Hutse V, Vranckx R (2005) Correlation between detection of antibodies against hepatitis C virus in oral fluid and hepatitis C virus RNA in serum. Eur J Clin Microbiol Infect Dis 24: 566–568.
- 11. Takahashi M, Saito H, Higashimoto M, Atsukawa K, Ishii H (2005) Benefit of hepatitis C virus core antigen assay in prediction of therapeutic response to interferon and ribavirin combination therapy. J Clin Microbiol 43: 186–191.
- 12. Memon MI, Memon MA (2002) Hepatitis C: an epidemiological review. J Viral Hepatitis 9: 84–100.
- 13. Rosenberg S (2001) Recent advances in the molecular biology of hepatitis C virus. J Mol Biol 313: 451–464.
- 14. Reed KE, Rice CM (2000) Overview of hepatitis C virus genome structure, polyprotein processing, and protein properties. Hep C Viruses 242: 55–84.
- 15. Flint M, McKeating JA (2000) The role of the hepatitis C virus glycoproteins in infection. Rev Med Virol 10: 101–117.
- 16. Cocquere L, Voisset C, Dubuisson J (2006) Hepatitis C virus entry: potential receptors and their biological functions. J Gen Virol 87: 1075–1084.
- 17. Pileri P, Uematsu Y, Campagnoli S, Galli G, Falugi F, et al. (1998) Binding of hepatitis C virus to CD81. Science 282: 938–941.
- 18. Bartosch B, Vitelli A, Granie C, Goujon C, Dubuisson J, et al. (2003) Cell entry of hepatitis C virus requires a set of co-receptors that include the CD81 tetraspanin and the SR-B1 scavenger receptor. J Biol Chem 278: 41624–41630.
- 19. Grove J, Nielsen S, Zhong J, Bassendine MF, Drummer HE, et al. (2008) Identification of a resident in hepatitis C virus E2 glycoprotein that determines scavenger receptor BI and CD81 receptor dependency and sensitivity to neutralizing antibodies. J Virol 82: 12020–12029.
- 20. Evans MJ, von Hahn T, Tscherne DM, Syder AJ, Panis M, et al. (2007) Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry. Nature 446: 801–805.
- 21. Bunka DH, Stockley PG (2006) Aptamers come of age - at last. Nat Rev Microbiol 4: 588–596.
- 22. Kikuchi K, Umehara T, Fukuda K, Hwang J, Kuno A, et al. (2003) RNA aptamers targeted to domain II of hepatitis C virus IRES that bind to its apical loop region. J Biochem 133: 263–270.
- 23. Hwang B, Cho JS, Yeo HJ, Kim JH, Chung KM, et al. (2004) Isolation of specific and high-affinity RNA aptamers against NS3 helicase domain of hepatitis C virus. RNA 10: 1277–1290.
- 24. Biroccio A, Hamm J, Incitti I, De Francesco R, Tomei L (2002) Selection of RNA aptamers that are specific and high-affinity ligands of the hepatitis C virus RNA-dependent RNA polymerase. J Virol 76: 3688–3696.
- 25. Cao X, Li S, Chen L, Ding H, Xu H, Huang Y, et al. (2009) Combining use of a panel of ssDNA aptamers in the detection of Staphylococcus aureus. Nucleic Acids Res 37: 4621–4628.
- 26. Gottwein JM, Scheel TK, Jensen TB, Lademann JB, Prentoe JC, et al. (2009) Development and characterization of hepatitis C virus genotype 1-7 cell culture systems: Role of CD81 and scavenger receptor class B type I and effect of antiviral drugs. Hepatology 49: 364–377.
- 27. Penin F, Combet C, Germanidis G, Frainais PO, Deléage G, et al. (2001) Conservation of the conformation and positive charges of hepatitis C virus E2 envelope glycoprotein hypervariable region 1 points to a role in cell attachment. J Virol 75: 5703–5710.
- 28. Simmonds P, Bukh J, Combet C, Deléage G, Enomoto N, et al. (2005) Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology 42: 962–973.
- 29. Lu L, Nakano T, He Y, Fu Y, Hagedorn CH, et al. (2005) Hepatitis C virus genotype distribution in China: predominance of closely related subtype 1b isolates and existence of new genotype 6 variants. J Med Virol 75: 538–549.
- 30. Oh HB, Kim SO, Cha CH, Hong SP, Folk WR, et al. (2008) Identification of hepatitis C virus genotype 6 in Korean patients by analysis of 5′ untranslated region using a matrix assisted laser desorption/ionization time of flight-based assay, restriction fragment mass polymorphism. J Med Virol 80: 1712–1719.
- 31. Ng EW, Shima DT, Calias P, Cunningham ET Jr, Guyer DR, et al. (2006) Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease. Nat Rev Drug Disciv 5: 123–132.
- 32. Dyke CK, Steinhubl SR, Kleiman NS, Cannon RO, Aberle LG, et al. (2006) First-in-human experience of an antidote-controlled anticoagulant using RNA aptamer technology: a phase 1a pharmacodynamic evaluation of a drug-antidote pair for the controlled regulation of factor IXa activity. Circulation 114: 2490–2497.
- 33. Li P, Wan Q, Feng Y, Liu M, Wu J, et al. (2007) Engineering of N-glycosylation of Hepatitis C Virus Envelope Protein E2 Enhances T cell responses for DNA immunization. Vaccine 25: 1544–1551.
- 34. Yang JH, Lai JP, Douglas SD, Metzger D, Zhu XH, et al. (2002) Real-time RT-PCR for quantitation of hepatitis C virus RNA. J Virol Methods 102: 119–128.
- 35. Liu J, Ali MA, Shi Y, Zhao Y, Luo F, Yu J, et al. (2009) Specifically binding of L-ficolin to N-glycans of HCV envelope glycoproteins E1 and E2 leads to complement activation. Cell Mol Immunol 6: 235–244.
- 36. Owsianka AM, Timms JM, Tarr AW, Brown RJ, Hickling TP, et al. (2006) Identification of conserved residues in the E2 envelope glycoprotein of the hepatitis C virus that are critical for CD81 binding. J Virol 80: 8695–8704.
- 37. Pan Q, Zhang XL, Wu HY, He PW, Wang F, et al. (2005) Aptamers that preferentially bind type IVB pili and inhibit human monocytic-cell invasion by Salmonella enterica serovar typhi. Antimicrob Agents Chemother 49: 4052–4060.
- 38. Cao J, Zhao P, Miao XH, Zhao LJ, Xue LJ, et al. (2003) Phage display selection on whole cells yields a small peptide specific for HCV receptor human CD81. Cell Res 13: 473–479.
- 39. Chen F, Zhou J, Luo F, Mohammed AB, Zhang XL (2007) Aptamer from whole-bacterium SELEX as new therapeutic reagent against virulent Mycobacterium tuberculosis. Biochem Bioph Res Co 357: 743–748.
- 40. Shangguan DH, Li Y, Tang ZW, Cao ZC, Chen HW, et al. (2006) Aptamers evolved from live cells as effective molecular probes for cancer study. Proc Natl Acad Sci USA 103: 11838–11843.